The Effect of Lifestyle-Adjustments Prior to Medical Treatment on the Effect of Medical Treatment in Reflux Patients

September 16, 2008 updated by: AstraZeneca
The purpose of this study is to determine whether the improvement in the quality of life after an initial treatment with esomeprazole 40mg for reflux disease is the same in patients who have already made lifestyle-adjustments as in patients who have not implemented lifestyle-adjustments prior to the start of treatment (baseline)

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

990

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Netherlands
      • Almere, Netherlands
        • Research Site
      • Apeldoorn, Netherlands
        • Research Site
      • Baarn, Netherlands
        • Research Site
      • Bennebroek, Netherlands
        • Research Site
      • Blaardingen, Netherlands
        • Research Site
      • Boekel, Netherlands
        • Research Site
      • Bunschoten Spakenburg, Netherlands
        • Research Site
      • Delft, Netherlands
        • Research Site
      • Den Haag, Netherlands
        • Research Site
      • Enschede, Netherlands
        • Research Site
      • Ewijk, Netherlands
        • Research Site
      • Geleen, Netherlands
        • Research Site
      • Haelen, Netherlands
        • Research Site
      • Halfweg NH, Netherlands
        • Research Site
      • Hardenberg, Netherlands
        • Research Site
      • Heemstede, Netherlands
        • Research Site
      • Hillegom, Netherlands
        • Research Site
      • Hilversum, Netherlands
        • Research Site
      • Horst, Netherlands
        • Research Site
      • Kerkrade, Netherlands
        • Research Site
      • Klimmen, Netherlands
        • Research Site
      • Landgraaf, Netherlands
        • Research Site
      • Laren, Netherlands
        • Research Site
      • Leusden, Netherlands
        • Research Site
      • Lichtenvoorde, Netherlands
        • Research Site
      • Lisse, Netherlands
        • Research Site
      • Maastricht, Netherlands
        • Research Site
      • Monster, Netherlands
        • Research Site
      • Nieuw Vennep, Netherlands
        • Research Site
      • Nieuwegein, Netherlands
        • Research Site
      • Nijverdal, Netherlands
        • Research Site
      • Ochten, Netherlands
        • Research Site
      • Oisterwijk, Netherlands
        • Research Site
      • Oldenzaal, Netherlands
        • Research Site
      • Pijnacker, Netherlands
        • Research Site
      • Rijnsburg, Netherlands
        • Research Site
      • Rijssen, Netherlands
        • Research Site
      • Schijndel, Netherlands
        • Research Site
      • Sittard, Netherlands
        • Research Site
      • Soest, Netherlands
        • Research Site
      • Susteren, Netherlands
        • Research Site
      • Swalmen, Netherlands
        • Research Site
      • Tilburg, Netherlands
        • Research Site
      • Vaals, Netherlands
        • Research Site
      • Valkenburg, Netherlands
        • Research Site
      • Veenendaall, Netherlands
        • Research Site
      • Velp, Netherlands
        • Research Site
      • Warnsveld, Netherlands
        • Research Site
      • Wassenaar, Netherlands
        • Research Site
      • Westerhaar-Vrienzenv Wijk, Netherlands
        • Research Site
      • Zandvoort, Netherlands
        • Research Site
      • Zevenhuizen, Netherlands
        • Research Site
      • Zoetermeer, Netherlands
        • Research Site
      • s-Gravenzande, Netherlands
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with reflux complaints
  • 18 years of age

Exclusion Criteria:

  • Restrictions as mentioned in the registration text
  • H2RA or PPI use in the month prior to inclusion

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Investigators

  • Study Chair: N van den Berk, AstraZeneca
  • Study Director: A Sellink, MD, AstraZeneca

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2004

Study Completion (Actual)

March 1, 2008

Study Registration Dates

First Submitted

August 29, 2007

First Submitted That Met QC Criteria

August 31, 2007

First Posted (Estimate)

September 3, 2007

Study Record Updates

Last Update Posted (Estimate)

September 17, 2008

Last Update Submitted That Met QC Criteria

September 16, 2008

Last Verified

September 1, 2008

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • N11

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Quality of Life

Clinical Trials on esomeprazole

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe